RESEARCH. The cost-effectiveness of screening for colorectal cancer

Telford, Jennifer J.; Levy, Adrian R.; Sambrook, Jennifer C.; Zou, Denise; Enns, Robert A.
September 2010
CMAJ: Canadian Medical Association Journal;9/7/2010, Vol. 182 Issue 12, p1307
Academic Journal
Background: Published decision analyses show that screening for colorectal cancer is cost-effective. However, because of the number of tests available, the optimal screening strategy in Canada is unknown. We estimated the incremental cost-effectiveness of 10 strategies for colorectal cancer screening, as well as no screening, incorporating quality of life, noncompliance and data on the costs and benefits of chemotherapy. Methods: We used a probabilistic Markov model to estimate the costs and quality-adjusted life expectancy of 50- year-old average-risk Canadians without screening and with screening by each test. We populated the model with data from the published literature. We calculated costs from the perspective of a third-party payer, with inflation to 2007 Canadian dollars. Results: Of the 10 strategies considered, we focused on three tests currently being used for population screening in some Canadian provinces: low-sensitivity guaiac fecal occult blood test, performed annually; fecal immunochemical test, performed annually; and colonoscopy, performed every 10 years. These strategies reduced the incidence of colorectal cancer by 44%, 65% and 81%, and mortality by 55%, 74% and 83%, respectively, compared with no screening. These strategies generated incremental cost-effectiveness ratios of $9159, $611 and $6133 per quality-adjusted life year, respectively. The findings were robust to probabilistic sensitivity analysis. Colonoscopy every 10 years yielded the greatest net health benefit. Interpretation: Screening for colorectal cancer is costeffective over conventional levels of willingness to pay. Annual high-sensitivity fecal occult blood testing, such as a fecal immunochemical test, or colonoscopy every 10 years offer the best value for the money in Canada.


Related Articles

  • Cost-Effectiveness of Colorectal Cancer Screening Protocols in Urban Chinese Populations. Huang, Weidong; Liu, Guoxiang; Zhang, Xin; Fu, Wenqi; Zheng, Shu; Wu, Qunhong; Liu, Chaojie; Liu, Yang; Cai, Shanrong; Huang, Yanqin // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    Colorectal cancer (CRC) takes a second and fourth position in the incidence and mortality lists respectively among all malignant tumors in urban populations in China. This study was designed to evaluate the cost-effectiveness of two different CRC screening protocols: faecal occult blood test...

  • Colorectal cancer screening in Canada: Why not consider nurse endoscopists? Rabeneck, Linda; Paszat, Lawrence F. // CMAJ: Canadian Medical Association Journal;8/5/2003, Vol. 169 Issue 3, p206 

    Presents comments on an article concerning the use of fecal occult blood testing for colorectal cancer screening in Canada. Use of colonoscopy for screening; Advantage of colonoscopy over (FOB) testing in detecting colorectal cancer; Percentage of reduction in the rate of death from...

  • Patient preferences for colorectal cancer screening. Leard, Lorriana E.; Savides, Thomas J.; Ganiats, Theodore G. // Journal of Family Practice;Sep1997, Vol. 45 Issue 3, p211 

    BACKGROUND. New guidelines include several options for colorectal cancer screening. The goal of this study was to assess patient preferences for rive approaches: no screening, fecal occult blood testing (FOBT), flexible sigmoidoscopy, barium enema, and colonoscopy. METHODS. Patients from...

  • Editorial: Taking FIT to the People: Out of the Office and Into the Mail. Levin, Theodore R // American Journal of Gastroenterology;Jan2012, Vol. 107 Issue 1, p108 

    Abstract: Colorectal cancer (CRC) screening is most commonly performed in the United States using an opportunistic approach: patients coming to a physician's office for other unrelated reasons are offered screening with either fecal occult blood tests or, more commonly, a referral for...

  • Physician-reported reasons for limited follow-up of patients with a positive fecal occult blood test screening result. Baig, Nadeem; Myers, Ronald E.; Turner, Barbara J.; Grana, James; Rothermel, Todd; Schlackman, Neil; Weinberg, David S. // American Journal of Gastroenterology;Sep2003, Vol. 98 Issue 9, p2078 

    : ObjectiveFecal occult blood testing (FOBT) screening can reduce colorectal cancer (CRC) mortality when patients with an abnormal result [FOBT(+)] undergo a complete diagnostic evaluation (colonoscopy or double-contrast barium enema with or without flexible sigmoidoscopy). The aim of this study...

  • Comparison of an Established Simple Office-Based Immunological FOBT With Fecal Tumor Pyruvate Kinase Type M2 (M2-PK) for Colorectal Cancer Screening: Prospective Multicenter Study. Shastri, Yogesh M.; Loitsch, Stefan; Hoepffner, Nicolas; Povse, Nada; Hanisch, Ernst; Rösch, Wolfgang; Mössner, Joachim; Stein, Jürgen M. // American Journal of Gastroenterology;Jun2008, Vol. 103 Issue 6, p1496 

    OBJECTIVES: The immunological fecal occult blood test (IFOBT) has established itself as a more precise marker for colorectal cancer (CRC) screening than traditional guaiac-based FOBT. The simpler, cheaper, and more convenient newer office-based IFOBTs have been validated for diagnosing CRC....

  • Trends and Determinants of Up-to-date Status with Colorectal Cancer Screening in Tennessee, 2002-2008. Veeranki, Sreenivas P.; Shimin Zheng // International Journal of Preventive Medicine;Jul2014, Vol. 5 Issue 7, p865 

    Background: Screening rates for colorectal cancer (CRC) are increasing nationwide including Tennessee (TN); however, their up-to-date status is unknown. The objective of this study is to determine the trends and characteristics of TN adults who are up-to-date status with CRC screening during...

  • Colonic Neoplasia in Asymptomatic Persons with Negative Fecal Occult Blood Tests: Influence of Age, Gender, and Family History. Rex, Douglas K.; Lehman, Glen A.; Ulbright, Thomas M.; Smith, Jennefer J.; Pound, David C.; Hawes, Robert H.; Helper, Debra J.; Wiersema, Maurits J.; Langefeld, Carl D.; Wei Li // American Journal of Gastroenterology;Jun1993, Vol. 88 Issue 6, p825 

    Six hundred twenty-one asymptomatic persons with negative fecal occult blood tests (ages 50-75 yr), including 496 with no known risk factors for colorectal cancer and 125 with a single first-degree relative with a history of colonic neoplasia developed after age 40, underwent screening...

  • Do benefits and barriers differ by stage of adoption for colorectal cancer screening? Rawl, S. M.; Menon, U.; Champion, V. L.; May, F. E.; Loehrer Sr., P.; Hunter, C.; Azzouz, F.; Monahan, P. O.; Skinner, C. S. // Health Education Research;Apr2005, Vol. 20 Issue 2, p137 

    In 2003, over 148 300 people were expected to be diagnosed and 56000 to die from colorectal cancer (CRC). First-degree relatives (FDRs) of people with colon cancer have a two- to eight- fold increased risk for CRC. Despite evidence that screening is effective, adherence with screening...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics